98 related articles for article (PubMed ID: 1702876)
1. Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines.
Pizzorno G; Sokoloski JA; Cashmore AR; Moroson BA; Cross AD; Beardsley GP
Mol Pharmacol; 1991 Jan; 39(1):85-9. PubMed ID: 1702876
[TBL] [Abstract][Full Text] [Related]
2. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
Matherly LH; Angeles SM; McGuire JJ
Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
[TBL] [Abstract][Full Text] [Related]
4. (6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells.
Pizzorno G; Moroson BA; Cashmore AR; Beardsley GP
Cancer Res; 1991 May; 51(9):2291-5. PubMed ID: 1707749
[TBL] [Abstract][Full Text] [Related]
5. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines.
Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP
J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310
[TBL] [Abstract][Full Text] [Related]
6. Induction of HL-60 leukemia cell differentiation by the novel antifolate 5,10-dideazatetrahydrofolic acid.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Res; 1989 Sep; 49(17):4824-8. PubMed ID: 2758415
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a relationship between intracellular GTP levels and the induction of HL-60 leukemia cell differentiation by 5,10-dideazatetrahydrofolic acid (DDATHF).
Sokoloski JA; Pizzorno G; Beardsley GP; Sartorelli AC
Oncol Res; 1993; 5(8):293-9. PubMed ID: 8012061
[TBL] [Abstract][Full Text] [Related]
8. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
9. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis.
Beardsley GP; Moroson BA; Taylor EC; Moran RG
J Biol Chem; 1989 Jan; 264(1):328-33. PubMed ID: 2909524
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
11. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
12. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
13. The stereospecific cytotoxic potency of (6R) and (6S)-5,10- dideazatetrahydrofolate correlates with cellular folylpolyglutamate synthetase levels.
Lehman NL
Biochimie; 1995; 77(4):273-8. PubMed ID: 8589057
[TBL] [Abstract][Full Text] [Related]
14. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
Habeck LL; Mendelsohn LG; Shih C; Taylor EC; Colman PD; Gossett LS; Leitner TA; Schultz RM; Andis SL; Moran RG
Mol Pharmacol; 1995 Aug; 48(2):326-33. PubMed ID: 7651366
[TBL] [Abstract][Full Text] [Related]
15. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
Pizzorno G; Mini E; Coronnello M; McGuire JJ; Moroson BA; Cashmore AR; Dreyer RN; Lin JT; Mazzei T; Periti P
Cancer Res; 1988 Apr; 48(8):2149-55. PubMed ID: 2450647
[TBL] [Abstract][Full Text] [Related]
16. Hydrolytic cleavage of methotrexate gamma-polyglutamates by folylpolyglutamyl hydrolase derived from various tumors and normal tissues of the mouse.
Samuels LL; Goutas LJ; Priest DG; Piper JR; Sirotnak FM
Cancer Res; 1986 May; 46(5):2230-5. PubMed ID: 2421872
[TBL] [Abstract][Full Text] [Related]
17. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase.
Sanghani SP; Moran RG
Biochemistry; 1997 Aug; 36(34):10506-16. PubMed ID: 9265631
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
20. Induction of HL-60 leukemia cell differentiation by tetrahydrofolate inhibitors of de novo purine nucleotide biosynthesis.
Sokoloski JA; Beardsley GP; Sartorelli AC
Cancer Chemother Pharmacol; 1991; 28(1):39-44. PubMed ID: 2040032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
